|Articles|January 11, 2010
Octagon's ViewPoint Supports EU Module 1 Specification
Advertisement
Octagon Research Solutions announced support for recent European Union requirements for electronic Common Technical Document (eCTD) Submissions with the general availability of the following new versions of its eCTD product suite:
- ViewPoint v.3.12.0
- Octagon’s eCTD Viewer, v.2.6.0
- Octagon’s eCTD Validator, v.2.6.0
A key feature of the new releases includes support across all three products for eCTD EU Module 1 Specification, version 1.4.
The new product releases include support for updated attributes, naming conventions and checksum information as detailed in the 1.4 specification. The European Union applies the eCTD Specification in the European region as defined by the ICH M2 Working Group and completes it with the EU Module 1 specification.
“Support for the latest EU specification is critical to Octagon’s global clients who are submitting eCTD applications in the European Union,” noted Kirk Gallion, president, Octagon Research Solutions, Inc. “We are committed to supporting these updates as the industry continues to realize the global benefits of electronic submissions in general and the eCTD in particular.”
The new product releases include support for updated attributes, naming conventions and checksum information as detailed in the 1.4 specification. The European Union applies the eCTD Specification in the European region as defined by the ICH M2 Working Group and completes it with the EU Module 1 specification.
“Support for the latest EU specification is critical to Octagon’s global clients who are submitting eCTD applications in the European Union,” noted Kirk Gallion, president, Octagon Research Solutions, Inc. “We are committed to supporting these updates as the industry continues to realize the global benefits of electronic submissions in general and the eCTD in particular.”
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement